On July 5, 2022, KeChow Pharma submitted an application for a pre-marketing communication meeting for its MEK inhibitor Tunlametinib Capsules, Beijing time. We received a written response from the Center for Drug Evaluation on September 15, 2022, approving our submission of the new drug marketing authorization application for Tunlametinib Capsules. Furthermore, they agreed to include this product in the priority review and approval process.

About KeChow Pharma

KeChow Pharma is dedicated to developing innovative treatments for tumors, free radical-related diseases, and other therapeutic areas. Its pipeline includes MEK inhibitor, chemoprotective agents, KRASG12C inhibitor, pan-RAF inhibitor, and multiple other tumor-targeted inhibitors. Notably, its MEK inhibitor, Tunlametinib (HL-085), has submitted a new drug application in China and is included in the CSCO guidelines. Another novel drug, a chemoprotective agent, demonstrates superior efficacy and safety compared to current clinical counterparts. All research efforts aim to address unmet clinical needs globally and within China by developing original small molecule drugs with “best-in-class” potential, bridging domestic gaps and fulfilling scientific aspirations to enhance quality of life.